CONTRAINDICATIONS
NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.

...CONTINUED BELOW

This animated sequence illustrates the mechanism of action (MOA) for NUCALA.
This presentation begins with a brief overview of relevant disease state information about severe asthma and eosinophils. It will cover the evolving concept of phenotyping and its role in clinical practice. A discussion about eosinophils as a biomarker in severe asthma will follow. The presentation concludes with a review of the clinical development program for NUCALA.
This presentation begins with an overview of disease state information, including a discussion of the definition of severe asthma and the proportion of the total asthma population who have severe asthma with an eosinophilic phenotype. An overview of the mechanism of action of NUCALA is also included.
This presentation features the profile of a patient who meets the criteria of severe asthma with an eosinophilic phenotype and is not responding to current therapies. One of the confirmatory clinical studies that evaluated the effect of NUCALA on exacerbations in patients with severe asthma with an eosinophilic phenotype is also discussed.
In addition to a patient profile, this presentation includes a review of the SIRIUS study. The SIRIUS study was one of the confirmatory clinical trials that evaluated the effect of NUCALA on oral corticosteroid dose in patients with severe asthma with an eosinophilic phenotype.
This video includes instructions for the manual reconstitution of NUCALA.
This video includes instructions for the mechanical reconstitution of NUCALA.

825656R0 September 2017